CyprusTuberculosis profile
Population  2015 1.2 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.1 (0.09–0.11)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0.02 (0–0.08)
Incidence  (includes HIV+TB) 0.072 (0.062–0.083) 6.2 (5.3–7.2)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.12 (0.09–0.15)
Incidence (MDR/RR-TB)** 0 (0–0) 0 (0–0)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females <0.01 (<0.01–<0.01) 0.042 (0.036–0.048) 0.045 (0.039–0.051)
Males 0 (0–0) 0.028 (0.022–0.033) 0.028 (0.022–0.033)
Total <0.01 (<0.01–<0.01) 0.069 (0.064–0.075) 0.072 (0.062–0.083)
TB case notifications, 2015  
Total cases notified 63
Total new and relapse 63
          - % tested with rapid diagnostics at time of diagnosis 8%
          - % with known HIV status  
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 78%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.02 (0.01–0.03)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  0
(0–6)
Estimated % of TB cases with MDR/RR-TB 0% (0–10) 0% (0–0)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 59% 39
Previously treated cases, excluding relapse, registered in 2014 50% 2
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data